The Branford, Conn-based pharmaceutical manufacturer and the United States
Adopted Names (USAN) Council, in consultation with the World Health
Organization (WHO), has approved of the nonproprietary name "adipiplon" for
Neurogen’s wholly-owned drug candidate for treatment of insomnia, formerly
known as NG2-73.
 
USAN is an organization specializing in the appropriate naming of drugs
based on simplicity and chemical relationships.
 
To date adipiplon—a partial GABA agonist preferential for the alpha-3
subtype receptor, which is associated with the reduction of anxiety, as well
as hypnotic, or sleep effects—has been tested in over 600 subjects in eight
clinical studies.
 
To read the full release, click here.